JP2006512090A5 - - Google Patents

Download PDF

Info

Publication number
JP2006512090A5
JP2006512090A5 JP2005507928A JP2005507928A JP2006512090A5 JP 2006512090 A5 JP2006512090 A5 JP 2006512090A5 JP 2005507928 A JP2005507928 A JP 2005507928A JP 2005507928 A JP2005507928 A JP 2005507928A JP 2006512090 A5 JP2006512090 A5 JP 2006512090A5
Authority
JP
Japan
Prior art keywords
seq
amino acids
acid sequence
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005507928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006512090A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/034348 external-priority patent/WO2005016233A2/en
Publication of JP2006512090A publication Critical patent/JP2006512090A/ja
Publication of JP2006512090A5 publication Critical patent/JP2006512090A5/ja
Pending legal-status Critical Current

Links

JP2005507928A 2002-10-31 2003-10-28 ボツリヌス神経毒b受容体およびその使用 Pending JP2006512090A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42295102P 2002-10-31 2002-10-31
US49812803P 2003-08-27 2003-08-27
PCT/US2003/034348 WO2005016233A2 (en) 2002-10-31 2003-10-28 Botulinum neurotoxin b receptors and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009229744A Division JP2010006833A (ja) 2002-10-31 2009-10-01 ボツリヌス神経毒b受容体およびその使用

Publications (2)

Publication Number Publication Date
JP2006512090A JP2006512090A (ja) 2006-04-13
JP2006512090A5 true JP2006512090A5 (enExample) 2006-06-01

Family

ID=34197667

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2005507928A Pending JP2006512090A (ja) 2002-10-31 2003-10-28 ボツリヌス神経毒b受容体およびその使用
JP2009229744A Pending JP2010006833A (ja) 2002-10-31 2009-10-01 ボツリヌス神経毒b受容体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009229744A Pending JP2010006833A (ja) 2002-10-31 2009-10-01 ボツリヌス神経毒b受容体およびその使用

Country Status (10)

Country Link
US (2) US20040191887A1 (enExample)
EP (1) EP1578382B1 (enExample)
JP (2) JP2006512090A (enExample)
AT (1) ATE442161T1 (enExample)
AU (1) AU2003304419A1 (enExample)
CA (1) CA2504532C (enExample)
DE (1) DE60329225D1 (enExample)
ES (1) ES2333319T3 (enExample)
IL (1) IL167943A (enExample)
WO (1) WO2005016233A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1578382B1 (en) * 2002-10-31 2009-09-09 Wisconsin Alumni Research Foundation Botulinum neurotoxin b receptors and use thereof
US7341843B2 (en) * 2003-04-11 2008-03-11 Allergan, Inc. Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
WO2006113648A2 (en) * 2005-04-18 2006-10-26 University Of Massachusetts Hn-33 compositions and methods
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
US7985554B2 (en) 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof
DE102005051789B4 (de) 2005-10-28 2014-08-07 Toxogen Gmbh Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
CN101932936B (zh) 2007-09-14 2016-04-27 拜奥麦迪逊公司 利用切割序列和间隔子的共振能量转移测定
US10908146B2 (en) 2011-06-01 2021-02-02 Biomadison, Inc. Compositions and methods for improving sensitivity in cell based assays
US9303285B2 (en) 2012-01-04 2016-04-05 Biomadison, Inc. Methods and compounds for increasing sensitivity of botulinum assays
US12422428B2 (en) 2011-06-01 2025-09-23 Biomadison, Inc. Compositions and methods for cell-based assays
LT2715355T (lt) 2011-06-01 2017-06-12 Biomadison, Inc. Ne fret (fluorescencijos rezonansinės energijos perdavimas) būdu atliekamas botulino tyrimas
US11325954B2 (en) 2011-06-01 2022-05-10 Biomadison, Inc. Compositions and methods for stability testing of botulinum toxin
WO2015021433A1 (en) 2013-08-09 2015-02-12 Biomadison, Inc. Botulinum toxin assay with improved sensitivity
JPWO2023210585A1 (enExample) * 2022-04-25 2023-11-02

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994995B1 (en) * 2001-03-16 2006-02-07 Lexicon Genetics Incorporated Human synaptotagmin and polynucleotides encoding the same
US8022172B2 (en) * 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
EP1578382B1 (en) * 2002-10-31 2009-09-09 Wisconsin Alumni Research Foundation Botulinum neurotoxin b receptors and use thereof
EP1751284A4 (en) * 2003-12-19 2010-01-13 Wisconsin Alumni Res Found METHOD AND COMPOSITIONS FOR DETECTING BOTULINUM NEUROTOXINE
EP1920248B1 (en) * 2005-04-05 2010-09-29 Allergan, Inc. Clostridial toxin activity assays
AU2006299933A1 (en) * 2005-08-02 2007-04-19 Planet Biotechnology, Inc. Improved chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
US7985554B2 (en) * 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof
WO2013011055A1 (en) * 2011-07-19 2013-01-24 ETH Zürich Means and methods for determining clostridial neurotoxins

Similar Documents

Publication Publication Date Title
JP2006512090A5 (enExample)
Sheng et al. Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity.
Khachigian et al. Egr-1-induced endothelial gene expression: a common theme in vascular injury
Takahashi et al. Endothelin in the gastrointestinal tract: presence of endothelinlike immunoreactivity, endothelin-1 messenger RNA, endothelin receptors, and pharmacological effect
EP3802922B1 (en) Novel immune checkpoint inhibitors
KR102019008B1 (ko) 메르스 코로나바이러스 뉴클레오캡시드 융합 단백질을 이용한 메르스 코로나바이러스 검출 방법
JP2004512022A5 (enExample)
EP2577315B1 (en) Markers for renal disease
JP2006523440A (ja) 若年性ヘモクロマトーシス遺伝子(hfe2a)、その発現産物および使用法
CA2869899C (en) A novel interferon-.lambda.4 (ifnl4) protein, related nucleic acid molecules, and uses thereof
JP2004512824A5 (enExample)
JPS61502491A (ja) 組織型およびウロキナ−ゼ型プラスミノ−ゲン活性化因子の阻害物質に対する診断検定
JPH1099087A5 (enExample)
Sabolic et al. Rat renal glucose transporter SGLT1 exhibits zonal distribution and androgen-dependent gender differences
Mägert et al. Uroguanylin: gene structure, expression, processing as a peptide hormone, and co-storage with somatostatin in gastrointestinal D-cells
JP2006518582A5 (enExample)
JP2006502738A5 (enExample)
JP2009297021A5 (enExample)
EP1141292A1 (en) Monocyte-derived nucleic acids and related compositions and methods
CN102731659B (zh) 一种6×His-C99重组蛋白及其制备方法和应用
JP2011115169A (ja) Kcnb:新規なカリウムチャネルタンパク質
US20060137029A1 (en) Novel G protein-coupled receptor encoding gene and diagnostic uses therefor
US8163500B2 (en) Polypeptides and methods for the specific detection of antibodies in patients with a Borrelia infection
WO2007086342A1 (ja) c-myc遺伝子転写抑制因子FIRのスプライシングバリアント又はイントロン2内の4塩基繰り返し配列による癌検出方法
JP5709815B2 (ja) 脳型有機アニオントランスポーターとその遺伝子